Characterization of demographics and NS5A genetic diversity for hepatitis C virus genotype 4-infected patients with or without cirrhosis treated with ombitasvir/paritaprevir/ritonavir

Autor: Rakesh Tripathi, Tatyana Dekhtyar, Thomas Reisch, Coleen Hall, Tami Pilot-Matias, N. Mobashery, Yao Yu, Rebecca Redman, Christine Collins, Michelle Irvin, Gretja Schnell, Preethi Krishnan, Jill Beyer

Publikováno v: Journal of Viral Hepatitis. 25:1078-1088

Hepatitis C virus (HCV) genotype 4 (GT4) is genetically diverse with 17 confirmed and 4 provisional subtypes. In this report, HCV GT4-infected patient samples from Phase 2/3 clinical studies were analysed to characterize global demographics and genet

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0a06aa33c72a8ee8634f7dd582889670
https://doi.org/10.1111/jvh.12906

Ombitasvir, paritaprevir, and ritonavir plus ribavirin for chronic hepatitis C virus genotype 4 infection in Egyptian patients with or without compensated cirrhosis (AGATE-II): a multicentre, phase 3, partly randomised open-label trial

Autor: Coleen Hall, Mohamed Hassany, Reham Soliman, N. Mobashery, Tarik Asselah, Rebecca Redman, Gamal Shiha, Roula B. Qaqish, Mohammad A. Mohey, Gamal Esmat, Ayman Yosry, Imam Waked, Wahid Doss, Naglaa Allam, Naglaa Zayed

Publikováno v: The Lancet Gastroenterology & Hepatology. 1:36-44

In Egypt, chronic hepatitis C virus (HCV) infection occurs in around 10% of the population (about 8 million individuals), and is a leading cause of liver cirrhosis, hepatocellular carcinoma, and mortality. Although HCV genotype 4 constitutes about 20

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3015ede8611b28d5be89e1e866c076b4
https://doi.org/10.1016/s2468-1253(16)30002-4

Ombitasvir plus paritaprevir plus ritonavir with or without ribavirin in treatment-naive and treatment-experienced patients with genotype 4 chronic hepatitis C virus infection (PEARL-I): a randomised, open-label trial

Autor: Stanislas Pol, Coleen Hall, Katarzyna Fleischer-Stępniewska, Tarik Asselah, N. Mobashery, K. Rajender Reddy, Tami Pilot-Matias, Regis A. Vilchez, Gretja Schnell, Rebecca Redman, Christophe Hézode, Patrick Marcellin, Marina Berenguer, Tarek Hassanein

Publikováno v: Lancet
r-IIS La Fe. Repositorio Institucional de Producción Científica del Instituto de Investigación Sanitaria La Fe
instname

Summary Background Hepatitis C virus (HCV) genotype 4 accounts for about 13% of global HCV infections. Because interferon-containing treatments for genotype 4 infection have low efficacy and poor tolerability, an unmet need exists for effective all-o

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d9053c04df842312aee6178d33929ce5
https://doi.org/10.1016/s0140-6736(15)60159-3

Long-term safety and efficacy of levodopa-carbidopa intestinal gel in advanced Parkinson's disease

Autor: Hubert H, Fernandez, James T, Boyd, Victor S C, Fung, Mark F, Lew, Ramon L, Rodriguez, John T, Slevin, David G, Standaert, Cindy, Zadikoff, Arvydas D, Vanagunas, Krai, Chatamra, Susan, Eaton, Maurizio F, Facheris, Coleen, Hall, Weining Z, Robieson, Janet, Benesh, Alberto J, Espay

Publikováno v: Movement disorders : official journal of the Movement Disorder Society. 33(6)

Levodopa-carbidopa intestinal gel (designated as carbidopa-levodopa enteral suspension in the United States) provides stable plasma levodopa concentrations and reduces motor fluctuations in advanced Parkinson's disease patients through continuous del

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=pmid________::37d1bdb94037832941fd44a56e29636a
https://pubmed.ncbi.nlm.nih.gov/29570853

Levodopa-Carbidopa Intestinal Gel in Advanced Parkinson'd Disease: Final 12-Month, Open-Label Results

Autor: Per Odin, Eduard Z. Yakupov, Jordan Dubow, Fabian Klostermann, Janet Benesh, Mark F. Lew, Anthony E. Lang, Oksana Suchowersky, Victor S.C. Fung, Sylvain Chouinard, Hubert H. Fernandez, Weining Z. Robieson, David G. Standaert, Robert A. Hauser, Krai Chatamra, Coleen Hall, Alberto J. Espay, Malcolm Steiger

Publikováno v: Movement Disorders

Motor complications in Parkinson's disease (PD) are associated with long-term oral levodopa treatment and linked to pulsatile dopaminergic stimulation. l-dopa-carbidopa intestinal gel (LCIG) is delivered continuously by percutaneous endoscopic gastro

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::dbc320a67b4131860fc420f30a809dcf
http://europepmc.org/articles/PMC4674978